Tuochao Biotech

Tuochao Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of next-generation multi-specific antibody therapies for oncology. The company focuses on designing biologics that can simultaneously modulate multiple immune pathways, aiming to enhance anti-tumor efficacy and overcome resistance mechanisms inherent in monotherapy. Its lead candidate, TCB-001, is a bispecific antibody targeting PD-L1 and 4-1BB designed to provide localized immune activation within the tumor microenvironment. Tuochao's pipeline also includes innovative bifunctional fusion proteins and antibodies targeting the TGF-beta and CTLA-4 pathways. By leveraging its proprietary engineering platforms, the company seeks to deliver differentiated immunotherapy solutions for patients with advanced solid tumors.